Explore

Trendline Trendline
Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus
Trendline Trendline
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition
Trendline Trendline
Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment
Trendline Trendline
NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment NTRX-07

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment NTRX-07

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment NTRX-07
Trendline Trendline
CGBIO Secures KRW 5.3 Billion in Contracts at KIMES 2026, Expanding Global Medical Device Reach

CGBIO Secures KRW 5.3 Billion in Contracts at KIMES 2026, Expanding Global Medical Device Reach

CGBIO Secures KRW 5.3 Billion in Contracts at KIMES 2026, Expanding Global Medical Device Reach
Trendline Trendline
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advancements

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advancements

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advancements
Trendline Trendline
Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio
Trendline Trendline
Evommune to Highlight MRGPRX2 Inhibition Potential in Migraine Treatment

Evommune to Highlight MRGPRX2 Inhibition Potential in Migraine Treatment

Evommune to Highlight MRGPRX2 Inhibition Potential in Migraine Treatment
Trendline Trendline
Decoy Therapeutics to Present Business Outlook at Virtual Investor Event

Decoy Therapeutics to Present Business Outlook at Virtual Investor Event

Decoy Therapeutics to Present Business Outlook at Virtual Investor Event
Trendline Trendline
Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast